Exchange Surveillance
No active ASM or GSM measures on this stock.
Price band — none
Price
Trading Data
range barsReturns
absolute and vs benchmark indexAbout the Company
Dr Reddy`s Laboratories has been cateringto the needs ofthe pharmaceutical sector for over two decades. Active Pharmaceutical Ingredients (API) are their core strength, having a wide range of portfolio.The company also manufactures generic medicines with business spread across India, Russia, US and Germany as well as Proprietary Products which inlcudes NCE research, biologics business and differentiated formulations conducted in the US. Under this the company has launched Grafeel(Filgrastim) and Reditux(Rituximab).
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- HQ
- Hyderabad, Telangana
- Chairman
- K Satish Reddy
- Registrar
- Bigshare Services Pvt. Ltd.
- Exchange
- NSE
- ISIN
- INE089A01031
Institutional Demand
passive ownership through ETFsContext
where this company sitsFrequently Asked
▶What is the share price of Dr Reddys Laboratories Ltd today?
Dr Reddys Laboratories Ltd (DRREDDY) is trading at ₹1,242.5. The price shown is the latest available from the exchange feed and updates through the trading session.
▶What is DRREDDY’s P/E ratio versus the sector?
DRREDDY trades at a P/E of 153.0. Its industry median is shown alongside it in Key Stats, so you can see at a glance whether the stock is priced above or below the businesses it competes with. A lower P/E is not automatically cheaper — it can also reflect slower expected growth.
▶What is DRREDDY’s dividend yield?
DRREDDY has a dividend yield of 0.66%, based on dividends declared over the last twelve months against the current price. The full dividend history is on the News & Filings tab.
▶What is DRREDDY’s 52-week high and low?
DRREDDY has traded between ₹1,101 and ₹1,414.9 over the past year. The Trading Data block shows where the current price sits inside that band.
▶What is the market capitalisation of Dr Reddys Laboratories Ltd?
Dr Reddys Laboratories Ltd has a market capitalisation of ₹1.01 lakh crore.
▶What is DRREDDY’s return on equity?
DRREDDY reports a return on equity of 10.2%. ROE measures profit generated per rupee of shareholder capital, and is most meaningful compared against others in Drug Manufacturers - Specialty & Generic.
▶Who are DRREDDY’s competitors?
The Peers block on this page lists other Drug Manufacturers - Specialty & Generic companies with their price, P/E and market capitalisation. The Valuation tab compares multiples against the industry median in more depth.
▶What is DRREDDY’s promoter holding?
Promoters hold 26.63% of DRREDDY. The Ownership tab shows the full shareholding pattern — promoter, FII, DII and public — and how each has moved across recent quarters.
▶Which indices include DRREDDY?
Index membership is listed in the Context block on this page, along with the weight DRREDDY carries in each. That weight is what determines how much passive money tracks the stock.
▶Is Dr Reddys Laboratories Ltd a good buy?
We do not publish buy or sell calls. What this page gives you instead is the evidence: our Value & Investment Index for where the price sits against its own history, the Fundamental Strength Index for the quality of the business, an investment checklist of criteria applied to every stock, and pros and cons generated from DRREDDY’s own numbers. The judgement is yours.
DRREDDY at a glance
Dr Reddys Laboratories Ltd operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector. Dr Reddys Laboratories Ltd (DRREDDY) last traded at ₹1,242.5, giving it a market capitalisation of ₹1.01 lakh crore. The 52-week range is ₹1,101 to ₹1,414.9, and the price is 45% of the way up that range. It trades at a price-to-earnings ratio of 153.0. Promoters hold 26.63% of the company in the latest shareholding filing.
| Market cap | ₹1.01 lakh crore |
|---|---|
| P/E | 153.0 |
| ROE | 10.2% |
| ROCE | 12.1% |